Skip to content
Subscriber Only

Lilly Profit Beats Analyst Estimates as Cymbalta Sales Rise

Eli Lilly & Co., maker of the schizophrenia medicine Zyprexa, reported second-quarter profit that fell less than analysts estimated after higher sales for the antidepressant Cymbalta helped trim losses from generic competition to its former top-seller.

Net income declined 23 percent to $924 million, or 83 cents a share, from $1.2 billion, or $1.07, a year earlier, Indianapolis-based Lilly said today in a statement. The per-share earnings beat the 77-cent average of 15 analysts’ estimates compiled by Bloomberg.